Contribution of TFH and of TREG cells to DSA generation in sensitized KTx recipients
Contribution of TFH and of TREG cells to DSA generation in sensitized KTx recipients
批准号:
8991720
负责人:
DIANA M METES
金额:
$15.13万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-01-08 至 2017-12-31
关键词:
AcuteAgeAllograftingAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAntibody AffinityAntibody FormationAntibody ResponseAntibody-Producing CellsAntithymoglobulinB-LymphocytesBLR1 geneBindingBiological MarkersCD4 Positive T LymphocytesCell physiologyCellsChronicClinicalClinical ResearchComplementControl GroupsDataDetectionDevelopmentDiseaseEarly DiagnosisEarly treatmentEtiologyEventFrequenciesFunctional disorderGenderGenerationsGraft RejectionGrantHealthHeartHelper-Inducer T-LymphocyteHomeostasisHumanIgG1IgG3IgG4ImmuneImmune responseImmunoglobulin Class SwitchingImmunoglobulin GImmunologicsImmunosuppressive AgentsIncidenceInfectionInflammatoryInjuryInstructionKidney TransplantationKnowledgeLeadLungMaintenanceMediatingMedicineMemoryMemory B-LymphocyteOrganOrgan TransplantationOutcomeOutputPatientsPhenotypePlasmablastPublic HealthRegimenRegulatory T-LymphocyteResearchRiskRoleSerumStagingT-LymphocyteT-Lymphocyte SubsetsTimeTransplant RecipientsTransplantationVaccinationbasecohortdesignend-stage organ failuregraft failurehigh riskimprovedmemory CD4 T lymphocytenoveloutcome forecastpathogenresponsetreatment choice
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Organ transplantation represents the treatment of choice for end-stage organ failure associated diseases. Despite the advancements in medicine and the availability of novel and more potent immunosuppressive regimens, the long-term allograft outcomes after organ transplantation remain poor, with an average of only 60% allograft survival by 10 years. Transplant rejection, is one of the most important causes of allograft dysfunction and loss, and consists of multi-layered cellular and humoral immunologic-triggered injuries. Approximately 30% of HLA-sensitized kidney transplant recipients present with DSA post-Tx, which significantly increase the risk for cellular- and antibody-mediated rejection (ACR, AMR). Although DSA represents an important biomarker for decreased allograft survival, till date the exact immune mechanisms implicated in DSA generation are not entirely understood. While DSA are affinity matured IgG Abs, indicating that they are generated with T cell help, the direct role of T follicular helper (TFH) cells during DSA development and maintenance, as well as their relationship with TREG and B cells has not been investigated in the field of transplantation, and remains to be elucidated. Our recent preliminary data show that in a cohort of Thymoglobulin-induced KTx recipients the overall % of circulating TFH cells in patients with DSA were not significantly different from those of age- and gender- matched healthy controls (HC) or of quiescent, DSA negative KTx recipients. However, DSA positive KTx patients display a significant skewing of TFH cell subsets toward a Th1-TFH phenotype, accompanied by a concomitant decrease in TREG that results in significantly elevated Th1-TFH:TREG ratio as compared to ratios from both control groups. Based on these results, our central hypothesis is that Th1-TFH, provide key help for memory B cells to differentiate into plasmablasts and produce recall DSA, and an imbalance between Th1-TFH and TREG which protect T helper cell immune homeostasis, correlates with the development of pathogenic DSA after KTx. Our specific aims are: 1) To determine the direct contribution of CXCR5+Th1 TFH to DSA generation in KTx recipients; 2) To study the role of TREG in tempering CXCR5+Th1 TFH cell function or in regulating B cell DSA production. This proposal will provide valuable mechanistic understanding of the roles of TFH and TREG in recall allo- immune responses that generate DSA after KTx. It will also provide a robust scientific platform for designing clinical studies aimed at enhancing the early detection and treatment of patients at risk of poor graft outcomes. Knowledge gained in kidney transplant recipients is likely to apply to recipients of other types of organ transplants, such as the heart and lung, where clinical outcomes lag significantly behind.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chronic High EBV load and risk of PTLD in Pediatric Heart Transplant Patients
-
批准号:7983632
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2010
-
负责人:DIANA M METES
-
依托单位:
Chronic High EBV load and risk of PTLD in Pediatric Heart Transplant Patients
-
批准号:8258732
-
项目类别:
-
资助金额:$37.14万
-
财政年份:2010
-
负责人:DIANA M METES
-
依托单位:
Chronic High EBV load and risk of PTLD in Pediatric Heart Transplant Patients
-
批准号:8109373
-
项目类别:
-
资助金额:$37.51万
-
财政年份:2010
-
负责人:DIANA M METES
-
依托单位:
Chronic High EBV load and risk of PTLD in Pediatric Heart Transplant Patients
-
批准号:8452060
-
项目类别:
-
资助金额:$35.36万
-
财政年份:2010
-
负责人:DIANA M METES
-
依托单位:
Core--Immunological Monitoring
-
批准号:7344812
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2007
-
负责人:DIANA M METES
-
依托单位:
Core B--Immunological Monitoring
-
批准号:7189870
-
项目类别:
-
资助金额:$49.42万
-
财政年份:2006
-
负责人:DIANA M METES
-
依托单位:
Core B--Immunological Monitoring
-
批准号:7062834
-
项目类别:
-
资助金额:$47.98万
-
财政年份:2005
-
负责人:DIANA M METES
-
依托单位:
Core B--Immunological Monitoring
-
批准号:6772600
-
项目类别:
-
资助金额:$47.64万
-
财政年份:2004
-
负责人:DIANA M METES
-
依托单位:
Core--Immunological Monitoring
-
批准号:7582414
-
项目类别:
-
资助金额:$39.81万
-
财政年份:--
-
负责人:DIANA M METES
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: